Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic
Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic
MVA-BN or Modified Vaccinia Ankara-On Thursday, the European Commission said around 100,000 mpox vaccine doses arrived in the Democratic Republic of Congo (DRC), making these the first delivery of the vaccine to the country.
週四，歐洲委員會表示，約有10萬劑mpox疫苗運抵剛果民主共和國（DRC），成爲該國首批疫苗輸送。
A second delivery amounting to around 100,000 vaccines is expected to arrive in the coming days.
預計在未來幾天內將有大約10萬劑疫苗的第二批運抵。
These vaccines are part of the 215,000 MVA-BN vaccine doses that the European Commission's Health Emergency Preparedness and Response Authority procured and pledged to share with affected African countries as an immediate response to the mpox outbreak.
這些疫苗是歐洲委員會衛生緊急事務與反應局採購的21.5萬劑MVA-BN疫苗之一，承諾與受影響的非洲國家共享，作爲對mpox爆發的直接應對。
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic A/S (OTC:BVNRY) (OTC:BVNKF) is a non-replicating smallpox vaccine and the only mpox vaccine approved in the EU/EEA and the U.K. (marketed as Imvanex), the U.S. and Switzerland (marketed as Jynneos), and in Canada (marketed as Imvamune).
MVA-BN或Modified Vaccinia Ankara-Bavarian Nordic A/S（OTC: BVNRY）（OTC: BVNKF）是一種非複製性天花疫苗，也是唯一獲得歐盟/歐洲經濟區和英國批准的mpox疫苗（市場上稱爲Imvanex），以及美國和瑞士（市場上稱爲Jynneos）以及加拿大（市場上稱爲Imvamune）。
An additional 351,500 doses from France, Germany, Spain, Malta, Portugal, Luxembourg, Croatia, Austria, Poland, and potentially some other Member States will be donated to the Africa CDC to distribute to affected countries.
法國、德國、西班牙、馬耳他、葡萄牙、盧森堡、克羅地亞、奧地利、波蘭和可能其他一些成員國的額外35.15萬劑疫苗將捐贈給非洲疾病控制與預防中心（Africa CDC），以分發給受影響的國家。
This brings the total vaccine doses donated from Team Europe to at least 566,500.
這將使Team Europe捐贈的疫苗總劑量至少達到56.65萬劑。
Congo received the doses on Thursday, more than 18 months after the country declared the situation an epidemic.
剛果在宣佈該國疫情爲流行病後的18個多月後於週四收到了這些疫苗。
Assigning blame for the sluggish distribution of mpox vaccines in Congo proves challenging due to a multitude of factors, the NPR report notes.
《全國公共電臺》的報道指出，由於多種因素，很難歸咎於剛果mpox疫苗分發緩慢的問題。
As of June 27, Congo's regulatory body had not approved mpox vaccines for use. Subsequent donations from the U.S. have been stalled as the Congolese government finalizes pre-shipment requirements, such as proper vaccine storage and handling.
截至6月27日，剛果的監管機構尚未批准使用mpox疫苗。隨後，美國的捐贈因剛果政府正在完成發運前的要求，比如正確的疫苗儲存和處理，而被擱置。
Many low- and middle-income countries rely on the World Health Organization (WHO) to evaluate vaccine safety and efficacy. Yet, the WHO has not approved any mpox vaccines, still relatively new, despite their authorization by U.S. and European health authorities during the global mpox outbreak in 2022.
許多低收入和中等收入國家依賴世界衛生組織（WHO）評估疫苗的安全性和有效性。然而，儘管在2022年全球mpox爆發期間獲得美國和歐洲衛生當局的授權，WHO仍未批准任何mpox疫苗，這些疫苗仍然相對較新。
There remain significant unknowns about the vaccines, especially regarding their effectiveness against the virus strain currently spreading in Congo, which has evolved into a new variant.
對於這些疫苗仍存在重要的未知因素，尤其是它們對目前在剛果傳播的病毒株的有效性，該病毒株已經演變成一種新變種。
The African response to the mpox crisis mirrors past challenges faced during the COVID pandemic when vaccine access was severely limited for lower-income nations.
對於低收入國家來說，在mpox危機中的非洲應對措施與過去COVID大流行時期面臨的挑戰相似，即疫苗獲取對這些國家嚴重受限。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
- 週五，與低價股和血癌公司Vor Biopharma有什麼新發展？
Photo by NIAID via Flickr
圖片由NIAID通過Flickr提供
